Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international bv - leptospira interrogans serotüüp canicola serotüübi portland-vere (tüvi ca-12-000), l. interrogans serotüüp icterohaemorrhagiae serotüübi copenhageni (tüvi ic-02-001), l. interrogans serotüüp australis serotüübi bratislava (tüvi, sest-05-073), l. kirschneri serotüüp grippotyphosa serotüübi dadas (tüvi gr-01-005) - immunoloogilised vahendid - koerad - aktiivse immuniseerimise koerte vastu:leptospira interrogans serotüüp canicola serotüübi canicola, et vähendada nakkuse ja eritumist uriiniga;l. interrogans serotüüp icterohaemorrhagiae serotüübi copenhageni, et vähendada nakkuse ja eritumist uriiniga;l. interrogans serotüüp australis serotüübi bratislava, et vähendada nakkuse;l. kirschneri serotüüp grippotyphosa serotüübi bananal / lianguang, et vähendada nakkuse ja eritumist uriiniga.

Euroopa Liit - eesti - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - live kasside panleucopenia viirus / parvovirus + live kasside rinotrahheiidi viiruse + live kasside calicivirus + inaktiveeritud kasside leukeemia viiruse - kassid - kasside aktiivseks immuniseerimiseks alates kaheksa nädala vanusest: kasside kalitsiviroos kliiniliste tunnuste vähendamiseks. kasside viiruslik rinotrahheiit kliiniliste tunnuste ja viiruse eritumise vähendamiseks. kasside panleukopeenia leukopeenia ärahoidmiseks ja kliiniliste tunnuste vähendamiseks. kasside leukeemia, et vältida püsivat viraemiat ja seonduva haiguse kliinilisi tunnuseid. algusega immuunsus: 3 nädalat pärast esmast vaktsineerimist jaoks panleucopenia ja leukeemia komponendid ja 4 nädala jooksul pärast esmase vaktsineerimise puhul calicivirus ja rinotrahheiidi viiruse komponendid. immuunsuse kestus: üks aasta pärast esmast vaktsineerimist kõikide komponentide jaoks.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Eesti - eesti - Ravimiamet

zoetis belgium - bordetella vaktsiin - suukaudse suspensiooni lüofilisaat ja lahusti - 1annus 5tk; 1annus 10tk; 1annus 25tk

Eesti - eesti - Ravimiamet

bioveta a.s. - bordetella vaktsiin+koerte paragripi elusviirusvaktsiin - ninatilgad, suspensiooni lüofilisaat ja lahusti - 1annus+1annus 0.5ml 1annus 5tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immuunsuse tagajärgi on tõestatud üks nädal pärast esmast vaktsinatsioonikursust rinotrahheiidi, kalitsiviiruse, chlamydophila felis ja panleukopeenia komponentide jaoks. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Eesti - eesti - Ravimiamet

octapharma (ip) - immunoglobuliin, intravaskulaarseks kasutamiseks - infusioonilahus - 50mg 1ml 200ml 1tk; 50mg 1ml 200ml 2tk; 50mg 1ml 50ml 1tk; 50mg 1ml 20ml 1tk; 50mg 1ml 200ml 3tk; 50mg 1ml 500ml 1tk

Eesti - eesti - Ravimiamet

octapharma (ip) - immunoglobuliin, intravaskulaarseks kasutamiseks - infusioonilahus - 100mg 1ml 50ml 1tk; 100mg 1ml 25ml 1tk; 100mg 1ml 60ml 1tk; 100mg 1ml 200ml 3tk; 100mg 1ml 10ml 1tk; 100mg 1ml 100ml 1tk